Biotechnology, Investing, Venture Capital, Science, Chemistry.
will likely use to establish various partnerships and develop a pipeline. I’ve always comped Eikon to Relay Therapeutics. But once Eikon does get committed to clinical assets, a second-generation of companies will likely emerge to convert data on live-cell protein motion into new medicines. But